Literature DB >> 31966989

DEPOT TRIAMCINOLONE INJECTION CONTRIBUTING TO ADRENAL SUPPRESSION AND CUSHING SYNDROME: CASE REPORT AND LITERATURE REVIEW.

Rachel E Modarelli, Matthew D Stephen.   

Abstract

OBJECTIVE: To present an unusual case of Cushing syndrome in a pediatric patient caused by a single depot triamcinolone injection.
METHODS: A case report followed by a literature review are presented.
RESULTS: A 13-year-old male presented with rapid weight gain, elevated blood pressure, headaches, and diffuse purplish striae. Lab results revealed a low 24-hour urinary free cortisol of <3 μg (reference range is 4.0 to 56 μg/24 hours), a low midnight salivary cortisol of <50 ng/dL (reference range is <100 ng/dL), a low adrenocorticotropic hormone of <5 pg/mL (reference range is 6 to 55 pg/mL), and a lower than expected testosterone of 86 ng/dL. The values were not consistent, and upon further questioning the family admitted the patient had received a "Jesus shot" from a practitioner which was sold as a cure all. Upon further investigation, it was determined that this injection contained both dexamethasone and depot triamcinolone. The triamcinolone in this injection was quantified and remained measureable for over 4 months following injection.
CONCLUSION: The cause of Cushing syndrome symptoms with adrenal suppression was exogenous glucocorticoid, specifically depot triamcinolone. Exogenous glucocorticoids can create adrenal suppression, contributing to life-threatening adrenal crises with illness or stress. Recovery of our patient's adrenal axis was demonstrable within a few months. This case highlights the potentially devastating effects of glucocorticoid treatment for unclear medical indications. Further, it raises concerns about the potential unintended consequences of such therapies and the importance for providers to raise additional questions whenever the clinical presentation and laboratory investigation are inconsistent.
Copyright © 2019 AACE.

Entities:  

Year:  2019        PMID: 31966989      PMCID: PMC6876975          DOI: 10.4158/ACCR-2018-0224

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  7 in total

1.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 2.  An update on Cushing syndrome in pediatrics.

Authors:  Constantine A Stratakis
Journal:  Ann Endocrinol (Paris)       Date:  2018-04-09       Impact factor: 2.478

3.  Why patients use alternative medicine: results of a national study.

Authors:  J A Astin
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

4.  Cushing's syndrome and adrenal insufficiency after intradermal triamcinolone acetonide for keloid scars.

Authors:  Martijn J J Finken; Dick Mul
Journal:  Eur J Pediatr       Date:  2010-02-26       Impact factor: 3.183

5.  Four cases of a secondary Cushingoid state following local triamcinolone acetonide (Kenacort) injection.

Authors:  T L Th A Jansen; E N Van Roon
Journal:  Neth J Med       Date:  2002-04       Impact factor: 1.422

Review 6.  Cushing's syndrome after intralesional triamcinolone acetonide: a systematic review of the literature and multinational survey.

Authors:  Rafi Fredman; Mayer Tenenhaus
Journal:  Burns       Date:  2012-10-23       Impact factor: 2.744

7.  Acute and persistent iatrogenic Cushing's syndrome after a single dose of triamcinolone acetonide.

Authors:  P Iglesias; J González; J J Díez
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.